Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No.90): A systematic review and economic analysis

Health Technology Assessment

Volumn 15, Issue 31, 2011, Pages 1-178

  Greenhalgh, J ^a   Bagust, A ^a   Boland, A ^a   Saborido, C Martin ^a   Oyee, J ^a   Blundell, M ^a   Dundar, Y ^a   Dickson, R ^a   Proudlove, C ^b   Fisher, M ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Pharmacy Practice Unit   (United Kingdom)

^c LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO;

ACUTE CORONARY SYNDROME; ATHEROTHROMBOSIS; BIBLIOGRAPHIC DATABASE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG WITHDRAWAL; DYSPEPSIA; ECONOMIC EVALUATION; EMBASE; EVENING DOSAGE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPOTENSION; INDIGESTION; LIVER FUNCTION; LONG TERM CARE; MEDLINE; MODIFIED DRUG RELEASE; MORNING DOSAGE; MORTALITY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POST HOC ANALYSIS; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH PAIN; STROKE; STROKE PATIENT; SYSTEMATIC REVIEW; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; VOMITING; WEB OF SCIENCE;

ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; BRAIN ISCHEMIA; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; HUMANS; MODELS, ECONOMIC; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TICLOPIDINE;

EID: 80053166543     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta15310     Document Type: Review

References (122)

1. Allender S, Peto V, Scarborough P, Kaur A, Rayner M.Coronary heart disease statistics.2008: URL: www.heartstats.org/homepage.asp
2. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Rother J, et al.One-year cardiovascular event rates in outpatients with atherothrombosis.JAMA 2007;297:1197-206.
3. Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, et al.Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.Health Technol Assess 2004;8(38).
4. National Institute for Health and Clinical Excellence (NICE).Myocardial infarction thrombolysis: guidance (TA52).2002.URL: http://guidance.nice.org.uk/TA52/Guidance/pdf/English (cited 26 January 2010).
5. Leonardi-Bee J, Bath PMW, Bousser MG, Davalos A, Diener HC, Guiraud-Chaumeil B, et al.Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.Stroke 2005;36:162-8.
6. Patient UK.Stroke.2009.URL: www.patient.co.uk/health/Stroke.htm (cited December 2009).
7. National Collaborating Centre for Chronic Conditions.Stroke: national clinical guideline for diagnosis and initial management of acute stroke and transient ischaemic attack (TIA).London: Royal College of Physicians; 2008.URL: www.nice.org.uk/nicemedia/pdf/CG68FullGuideline.pdf
8. Scarborough P, Peto V, Bhatnagar P, Kaur A, Leal J, Luengo-Fernandez R, et al.Stroke statistics.Oxford: British Heart Foundation Health Promotion Research Group and Health Economics Research Centre; 2009.
9. Verro P, Gorelick PB, Nguyen D.Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis.Stroke 2008;39:1358-63.
10. National Prescribing Centre.Antiplatelet agents for stroke patients.MeReC Bull 2003;14:5-8.
11. Kirshner HS.Therapeutic interventions for prevention of recurrent ischemic stroke.Am J Manag Care 2008;14(Suppl.2):212-26.
12. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al.Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack.Circulation 2006;113:e409-49.
13. De Schryver E, Algra A, Van Gijn J.Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.Cochrane Database Syst Rev 2007;4:CD006186.
14. Selvin E, Erlinger T.Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.Circulation 2004;110:738-43.
15. Shammas NW.Epidemiology, classification, and modifiable risk factors of peripheral arterial disease.Vasc Health Risk Manag 2007;3:229-34.
16. National Institute for Health and Clinical Excellence (NICE).Final scope for the appraisal of clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of TA 90).London: NICE; 2009.URL: http://guidance.nice.org.uk/TA/WaveR/19/FinalScope (cited July 2009).
17. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau C-S, et al.The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design.Am Heart J 2006;151:786, el-10.
18. Target PAD.Reducing the risks from leg arterial disease.December 2009.URL: www.targetpad.co.uk/index.aspx
19. Scottish Intercollegiate Guidelines Network (SIGN).Diagnosis and management of peripheral artery disease: a national clinical guideline.2006.URL: www.sign.ac.uk/pdf/sign89.pdf
20. Aronow H, Hiatt WR.The burden of peripheral artery disease and the role of antiplatelet therapy.Postgrad Med J 2009;121:123-35.
21. Disabled World.Peripheral artery disease (PAD): facts, diagnosis and treatment.2009.URL: www.disabled-world.com/health/cardiovascular/peripheral-artery-disease.php (cited December 2009).
22. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas J-L, et al.International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.JAMA 2006;295:180-9.
23. Adamson J, Beswick A, Ebrahim S.Stroke and disability.J Stroke Cerebrovasc Dis 2004;13:171-7.
24. National Institute for Health and Clinical Excellence (NICE).Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA90).London: NICE; 2005.URL: http://guidance.nice.org.uk/TA90/Guidance/pdf/English (cited July 2009).
25. National Institute for Health and Clinical Excellence (NICE).Unstable angina and NSTEMI: the early management of unstable angina and non-ST-segment-elevation myocardial infarction.London: NICE; 2010.URL: http://guidance.nice.org.uk/CG94/Guidance/pdf/English (cited 25 March 2010).
26. The CAPRIE Steering Committee.A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).CAPRIE Steering Committee.Lancet 1996;348:1329-39.
27. The CURE trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-elevation.N Engl J Med 2001;345:494-502.
28. National Institute for Health and Clinical Excellence (NICE).Secondary prevention in primary and secondary care for patients following a myocardial infarction.Clinical Guideline 48.2007.URL: http://guidance.nice.org.uk/CG48/Guidance/pdf/English
29. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al.Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.Lancet 2005;366:1622-32.
30. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A.European Stroke Prevention Study 2.Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.J Neurol Sci 1996;143:1-13.
31. NHS Business Services Authority.Prescription services.2009.URL: www.nhsbsa.nhs.uk/PrescriptionServices/Documents/PPDPrescribingAnalysisCharts/NPC_Cardio_Jul_2009.pdf (cited 2009, 2 February 2010).
32. British Medical Association and Royal Pharmaceutical Society of Great Britain.British national formulary.No.58, September 2009.London: BMA and RPS; 2009.URL: http://bnf.org/bnf/index.htm
33. NHS Business Services Authority.Electronic drug tariff.2010.URL: www.ppa.org.uk/edt/February_2010/mindex.htm (cited 3 February 2010).
34. NHS Business Services Authority.Category Mprices.2010.URL: www.nhsbsa.nhs.uk/PrescriptionServices/1821.aspx (cited 11 April 2010).
35. European Medicines Agency.Generic clopidogrel.2010; URL: www.ema.europa.eu/search.php?q=generic+clopidogrel&spell=1&site=ema_collection&client=ema_frontend&access=p&ie=UTF-8&proxystylesheet=ema_frontend&output=xml_no_dtd
36. Medicines and Healthcare products Regulatory Agency (MHRA).2009.URL: www.mhra.gov.uk/index.htm
37. Department of Health. Saving lives: our healthier nation.1999.URL: www.archive.official-documents.co.uk/document/cm43/4386/4386.htm
38. Department of Health (DoH). National Standards, Local Action: Health and Social Care standards and planning framework 2005/6-2007/8.London: DoH; 2004.
39. Welsh Assembly Government.Health status Wales 2004/5: chief medical officer's report series.2005; URL: www.p2.wales.nhs.uk/news/3002 (cited December 2009).
40. Welsh Assembly Government.Health gain targets: national high-level targets and indicators for Wales.2008.URL: http://wales.gov.uk/topics/health/research/research/gain/;jsessi onid=n5WNLBjQd1202WxYDn7H2h2YgY15W0kTWP6mMy6jsMHRWHyJdLTv!-689210129?lang=en (cited December 2009).
41. Quality and Outcomes Framework (QOF).QOF database.2009.URL: www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4078659.pdf (cited 2009).
42. Belch J.Peripheral arterial disease: still on the periphery? Br Med J 2006;332: 1213.
43. Department of Health (DoH).National Service Framework for Coronary Heart Disease.2000.URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4094275 (cited December 2009).
44. Department of Health (DoH).National Service Framework for Coronary Heart Disease.2005.URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4105281 (cited December 2009).
45. National Institute for Health and Clinical Excellence (NICE).Clopidogrel in the treatment of non-ST-segment elevation acute coronary syndrome (TA80).London: NICE; 2004.URL: http://guidance.nice.org.uk/TA80/Guidance/pdf/English (cited July 2009).
46. Department of Health (DoH).National Stroke Strategy.2007.URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081062 (cited December 2009).
47. UK National Screening Centre.The handbook for vascular risk assessment, risk reduction and risk management.2008.URL: www.screening.nhs.uk/vascular (cited 2 February 2010).
48. Sanofi-aventis and Bristol-Myers Squibb.Plavix: summary of product characteristics.2009; URL: www.sanofi-aventis.co.uk/products/Plavix_SPC.pdf
49. Electronic Medicines Compendium.Browse medicines.2009.URL: http://emc.medicines.org.uk/browsedocuments.aspx (cited December 2009).
50. Medicines and Healthcare products Regulatory Agency and Commission on Human Medicines.Drug safety update.2010.URL: www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/index.htm
51. Boehringer Ingelheim. Submission to NICE to support the review of health technology appraisal 90: clopidogrel and modified-release dipyridamole and aspirin for the prevention of occlusive vascular events.Bracknell: Boehringer Ingelheim; 2009.
52. Sanofi-aventis and Bristol-Myers Squibb. The use of clopidogrel hydrogen sulphate (Plavix) in patients with atherosclerotic disease: manufacturer submission.Montreal, QC: Bristol-Myers Squibb; 2009.
53. Centre for Reviews and Dissemination.Systematic reviews: CRDs guidance for undertaking reviews in healthcare.URL: www.york.ac.uk/inst/crd/darefaq.htm (cited December 2009).
54. Drummond MF, Jefferson TO.Guidelines for authors and peer reviewers of economic submissions to the BMJ.The BMJ Economic Evaluation Working Party.Br Med J 1996;313:275-83.
55. Moher D, Liberati A, Tetzlaff J, Altman D.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.PLoS Med 2009;6: e1000097.URL: www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000097
56. ESPRIT Study Group.Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.Lancet 2006;367:1665-73.
57. Sacco RL, Diener H, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al.Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.N Engl J Med 2008;359:1238-51.
58. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al.Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.Lancet 2004;364:331-7.
59. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.N Engl J Med 2006;354:1706-17.
60. Van Swieten J, Koudstaal P, Visser M, Schouten H, van Gijn J.Interobserver agreement for the assessment of handicap in stroke patients.Stroke 1988;19:604-7.
61. Multi-parameter Evidence Synthesis Research Group (MPES).Mixed treatment comparisons (MTC).Bristol: University of Bristol; 2009.
62. Lunn D, Thomas A, Best N, Spiegelhalter D.Winbugs: a Bayesian modelling framework: concepts, structure, and extensibility.Stat Comput 2000;10:325-37.
63. Brooks SP, Gelman A.Alternative methods for monitoring convergence of iterative simulations.J Comp Graph Stats 1998;7:434-55.
64. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W.Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.Stroke 2004;35:528-32.
65. Rankin J.Cerebral vascular accidents in patients over the age of 60: II.Prognosis.Scot Med J 1957;2:200-15.
66. Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients.BMJ 2002;324:71-86.
67. Montori VM, Permanyer-Miralda G, Ferreira-Gonzalez I, Busse JW, Pacheco-Huergo V, Bryant D, et al.Validity of composite end points in clinical trials.BMJ 2005;330:594-6.
68. Tomlinson G, Detsky A.Composite end points in randomized trials: there is no free lunch.JAMA 2010;303:267-8.
69. Annemans L, Lamotte M, Levy E, Lenne X.Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial (Structured abstract).J Med Econ 2003: URL: www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22003008271/frame.html
70. Beard SM, Gaffney L, Bamber L, De Platchett J.Economic modelling of antiplatelet therapy in the secondary prevention of stroke.J Med Econ 2004;7:117-34.
71. Berger K, Hessel F, Kreuzer J, Smala A, Diener HC. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.Curr Med Res Opin 2008;24:267-74.
72. Chen J, Bhatt DL, Dunn ES, Shi CX, Caro JJ, Mahoney EM, et al.Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.Value Health 2009;12:872-9.
73. Karnon J, Brennan A, Pandor A, Fowkes G, Lee A, Gray D, et al.Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK.Curr Med Res Opin 2005;21:101-12.
74. Matchar DB, Samsa GP, Liu S.Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.Value Health 2005;8:572-80.
75. Schleinitz MD, Weiss JP, Owens DK.Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.Am J Med 2004;116:797-806.
76. Delea TE, Edelsberg JS, Richardson E, Singer DE, Oster G.Cost-effectiveness of clopidogrel in patients with ischemic stroke, myocardial infarction, or peripheral arterial disease.Value Health 2003;6:184-5.
77. Palmer AJ, Roze S, Hankey G, Hakimi Z, Spiesser J, Carita P, et al.Cost-effectiveness of clopidogrel versus aspirin in the prevention of ischemic events in stroke and TIA patients: a four-European country analysis.Value Health 2005;8:334.
78. Stevenson MD, Rawdin AC, Karnon JD, Brennan A.Clopidogrel is cost-effective compared with aspirin in United Kingdom patients with a myocardial infarction who subsequently sustain an ischaemic stroke or peripheral arterial disease event.Value Health 2008;11:A194-5.
79. van Hout BA, Tangelder MJD, Bervoets P, Gabriel S.Cost-effectiveness analysis of antithrombotic treatment with clopidogrel in patients with myocardial infarction, stroke, and peripheral arterial disease in the Netherlands.Value Health 2003;6:653.
80. Matchar DB, Samsa GP, Matthews JR, Ancukiewicz M, Parmigiani G, Hasselblad V, et al.The Stroke Prevention Policy Model: linking evidence and clinical decisions.Ann Intern Med 1997;127:704-11.
81. Chambers M, Hutton J, Gladman J.Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK.Aspirin, dipyridamole and aspirin-dipyridamole.Pharmacoeconomics 1999;16:577-93.
82. Diener HC, Rupprecht HJ, Willich SN.Cost of atherothrombotic diseases: myocardial infarction (MI), ischaemic stroke (IS) and peripheral arterial occlusive disease (PAD).J Public Health 2005;13:216-24.
83. Tengs TO, Lin TH.A meta-analysis of quality-of-life estimates for stroke.Pharmacoeconomics 2003;21:191-200.
84. Robinson M, Ginnelly L, Sculpher M, Jones L, Riemsma R, Palmer S, et al.A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists.Health Technol Assess 2002;6(25).
85. Derdeyn CP, Powers WJ.Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease.Stroke 1996;27:1944-50.
86. Zeckhauser R, Shepard D.Where now for saving lives? Law Contemp Probl 1976;40:5-45.
87. Haigh R, Castleden M, Woods K, Fletcher S, Bowns I, Gibson M, et al.Management of myocardial infarction in the elderly: admission and outcome on a coronary care unit.Health Trends 1991;23:154-7.
88. Lee TT, Solomon NA, Heidenreich PA, Oehlert J, Garber AM.Cost-effectiveness of screening for carotid stenosis in asymptomatic persons.Ann Intern Med 1997;126:337-46.
89. Danese MD, Powe NR, Sawin CT, Ladenson PW.Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis.JAMA 1996;276:285-92.
90. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C.Long-term risk of recurrent stroke after a first-ever stroke.The Oxfordshire Community Stroke Project.Stroke 1994;25:333-7.
91. Bruins Slot K. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies.BMJ 2008;336:40.
92. Personal Social Services Research Unit (PSSRU).Unit Costs of Health and Social Care 2007.2007.URL: www.pssru.ac.uk/uc/uc2007contents.htm
93. Medicare Information Management System (MIMS).The prescribing reference for general practice.2009.URL: www.mims.co.uk/(cited June 2009).
94. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No.57, March 2009.London: BMA and RPS; 2009.URL: http://bnf.org/bnf/index.htm
95. Diener H-C, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al.Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.Lancet Neurology 2008;7:875-84.
96. Miller G, Randolph S, Forkner E, Smith B, Galbreath AD.Long-term cost-effectiveness of disease management in systolic heart failure.Med Decis Making 2009;29:325-33.
97. Galbreath AD, Krasuski RA, Smith B, Stajduhar KC, Kwan MD, Ellis R, et al.Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure.Circulation 2004;110:3518-26.
98. Smith B, Forkner E, Zaslow B, Krasuski RA, Stajduhar K, Kwan M, et al.Disease management produces limited quality-of-life improvements in patients with congestive heart failure: evidence from a randomized trial in community-dwelling patients.Am J Manag Care 2005;11:701-13.
99. Robinson A, Thomson R, Parkin D, Sudlow M, Eccles M.How patients with atrial fibrillation value different health outcomes: a standard gamble study.J Health Serv Res Policy 2001;6:92-8.
100. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118:47-51.
101. Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, Rother J, et al.Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry.Eur Heart J 2009;30:2318-26.
102. Youman P, Wilson K, Harraf F, Kalra L.The economic burden of stroke in the United Kingdom.Pharmacoeconomics 2003;21(Suppl.1):43-50.
103. Clarke P, Gray A, Legood R, Briggs A, Holman R.The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No.65).Diabet Med 2003;20:442-50.
104. Heeg B, Damen J, Van Hout B.Oral antiplatelet therapy in secondary prevention of cardiovascular events: An assessment from the payer's perspective.Pharmacoeconomics 2007;25:1063-82.
105. National Institute for Health and Clinical Excellence (NICE).Atrial fibrillation: the management of atrial fibrillation.Clinical Guideline 36.London: NICE; 2006.URL: www.nice.org.uk/nicemedia/pdf/cg036fullguideline.pdf (cited July 2009).
106. Morant SV, McMahon AD, Cleland JG, Davey PG, MacDonald TM.Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity.Br J Clin Pharmacol 2004;57:188-98.
107. Luengo-Fernandez R, Gray AM, Rothwell PM.Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom.Stroke 2006;37:2579-87.
108. Department of Health (DoH). Health Survey for England 1996.Joint Surveys Unit of Social and Community Planning Research, and Department of Epidemiology and Public Health, University College London.London: DoH; 2001.
109. British Medical Association and Royal Pharmaceutical Society of Great Britain.British national formulary.No.60, March 2010.London: BMA and RPS; 2010.URL: http://bnf.org/bnf/index.htm
110. Department of Health (DoH).NHS Reference Costs 2008-2009.2010.URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591 (cited March 2010).
111. Sullivan P, Arant T, Ellis S, Ulrich H.The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at risk of stroke in the US.Pharmacoeconomics 2006;24:1021-33.
112. O'Brien C, Gage B.Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.JAMA 2005;293:699-706.
113. Jansen JP, Pellissier J, Choy EH, Ostor A, Nash JT, Bacon P, et al.Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK.Curr Med Res Opin 2007;23:3069-78.
114. Quinn R, Naimark D, Oliver M, Bayoumi A.Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.Am J Kidney Dis 2007;50:421-32.
115. Clarke P, Gray A, Holman R.Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).Med Decis Making 2002;22:340-9.
116. Dennis M, Bamford J, Sandercock P, Warlow C.Prognosis of transient ischemic attacks in the Oxfordshire community stroke project.Stroke 1990;21:848-53.
117. Hill M, Yiannakoulias N, Jeerakathil T, Tu J, Svenson L, Schlopflocher D.The high risk of stroke immediately after transient ischemic attack: a population-based study.Neurology 2004;62:2015-20.
118. Steg P, Goldberg R, Gore J, Fox K, Eagle K, Flather M, et al.Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE).Am J Cardiol 2002;90:358-63.
119. Antithrombotic Trialists Collaboration.Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.Lancet 2009;373:1849-60.
120. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR.Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.JAMA 2009;301:1909-19.
121. Halkes PHA, Gray LJ, Bath PMW, Diener HC, Guiraud-Chaumeil B, Yatsu FM, et al.Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk.J Neurol Neurosurg Psychiatry 2008;79:1218-23.
122. Sudlow C, Mason G, Maurice J, Wedderburn C, Hankey G.Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.Cochrane Database Syst Rev 2009;4:CD001246.